BioSpace News Archive

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced the presentation of additional data from the first cohort of patients in the Company’s Phase 1b clinical trial of RGLS4326 for the treatment of autosomal dominant polycystic kidney disease, as well as new preclinical data from relevant animal models of the disease.

Antibe Therapeutics Inc., a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to target inflammation in a wide range of health conditions, announced a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and fortify Antibe’s intellectual property position for its current pipeline.

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

The European Commission has approved Sanofi and Regeneron’s PD-1 inhibitor Libtayo® for the first-line treatment of adults with non-small cell lung cancer whose tumor cells have ≥50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations.

Hypertension is one of the common untreated diseases and poses major risk for heart failure, renal failure, cerebrovascular disease, cardiovascular disease, and coronary heart disease.

Fact.MR: The optometry equipment market revenue surpassed US$3.8 Bn for 2018, according to Fact.MR. The optometry equipment overall market is expected to gain US$ 2 Billion worth incremental opportunity by 2029.

Fact MR: The cervical dysplasia diagnostics market reported positive year over year growth in 2021. Fact.MR estimates the cervical dysplasia diagnostics market to exhibit a CAGR of 7% between 2021 and 2031.

Nicox SA, an international ophthalmology company, announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has received approval for VYZULTA®, 0.024% in the United Arab Emirates.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved the PD-1 inhibitor Libtayo® to treat adults with locally advanced or metastatic basal cell carcinoma who have progressed on or are intolerant to a hedgehog pathway inhibitor.

InxMed Co., Ltd. announced one study in collaboration with Ruijin Hospital, Shanghai Jiaotong University School of Medicine made an online publication on Advanced Science titled “Focal Adhesion Kinase Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling”.